Investigational drug · Phase 2
AZD8205
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AZD8205"
First trial start
2021
Oct 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD8205", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Biliary Tract Carcinoma
- Ovarian Cancer
- Endometrial Cancer
- Squamous Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Endometrial cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD8205" as an intervention, largest first.
- Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07044336 · 800 participants (planned) · Start Aug 1, 2025 · Primary completion Oct 15, 2027
Drug: Puxitatug Samrotecan; Doxorubicin and 1 more · For: Endometrial Cancer; Malignant Solid Tumour
Sites: Tucson, Arizona; La Jolla, California; Los Angeles, California · 320 sites in all
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05123482 · 460 participants (planned) · Start Oct 18, 2021 · Primary completion Sep 29, 2027
Drug: AZD8205; AZD8205 and AZD2936 (Rilvegostomig) and 4 more · For: Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer and 2 more
Sites: Duarte, California; Irvine, California; Santa Monica, California · 67 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07162480 · 28 participants (planned) · Start Apr 29, 2026 · Primary completion Dec 31, 2029
Drug: P-Sam · For: Adenoid Cystic Carcinoma
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review.
Phipps M, Falchook GS · J Immunother Precis Oncol 2025
- Detailed Structural Elucidation of Antibody-Drug Conjugate Biotransformation Species Using High Resolution Multiple Reaction Monitoring Mass Spectrometry with Orthogonal Dissociation Methods.
Yang J, Tan HY, Yuan J, et al. · ACS Pharmacol Transl Sci 2025
- Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo.
Huang Y, Tan HY, Yuan J, et al. · Anal Chem 2024
- Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.
Sousa LG, McGrail DJ, Lazar Neto F, et al. · Clin Cancer Res 2023
- Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Kinneer K, Wortmann P, Cooper ZA, et al. · Clin Cancer Res 2023
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.